Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells $981,243.93 in Stock

Blueprint Medicines Co. (NASDAQ:BPMCGet Free Report) insider Debra Durso-Bumpus sold 8,817 shares of the stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $111.29, for a total transaction of $981,243.93. Following the sale, the insider now directly owns 43,763 shares in the company, valued at $4,870,384.27. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Debra Durso-Bumpus also recently made the following trade(s):

  • On Friday, July 5th, Debra Durso-Bumpus sold 3,850 shares of Blueprint Medicines stock. The shares were sold at an average price of $111.20, for a total value of $428,120.00.
  • On Friday, June 28th, Debra Durso-Bumpus sold 333 shares of Blueprint Medicines stock. The shares were sold at an average price of $111.15, for a total value of $37,012.95.
  • On Friday, June 21st, Debra Durso-Bumpus sold 74,034 shares of Blueprint Medicines stock. The shares were sold at an average price of $104.19, for a total transaction of $7,713,602.46.

Blueprint Medicines Stock Performance

NASDAQ BPMC traded up $4.49 during trading on Monday, hitting $116.19. The company’s stock had a trading volume of 876,175 shares, compared to its average volume of 709,537. Blueprint Medicines Co. has a 52 week low of $43.89 and a 52 week high of $119.30. The firm has a market cap of $7.28 billion, a P/E ratio of -24.41 and a beta of 0.63. The firm has a 50 day moving average price of $105.08 and a 200 day moving average price of $93.57. The company has a quick ratio of 3.61, a current ratio of 3.76 and a debt-to-equity ratio of 0.67.

Blueprint Medicines (NASDAQ:BPMCGet Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($1.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.64) by $0.32. Blueprint Medicines had a negative net margin of 102.15% and a negative return on equity of 193.48%. The firm had revenue of $96.12 million during the quarter, compared to the consensus estimate of $82.58 million. Equities research analysts forecast that Blueprint Medicines Co. will post -5.15 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. StockNews.com raised shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a research note on Friday, May 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $130.00 price objective on shares of Blueprint Medicines in a report on Friday, June 28th. Stifel Nicolaus increased their price target on Blueprint Medicines from $120.00 to $130.00 and gave the company a “buy” rating in a research note on Friday, April 26th. Leerink Partnrs upgraded shares of Blueprint Medicines from an “underperform” rating to a “market perform” rating in a research report on Monday, May 6th. Finally, SVB Leerink upgraded shares of Blueprint Medicines from an “underperform” rating to a “market perform” rating and boosted their target price for the stock from $50.00 to $97.00 in a report on Monday, May 6th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Blueprint Medicines presently has a consensus rating of “Moderate Buy” and an average price target of $112.87.

Get Our Latest Stock Report on Blueprint Medicines

Hedge Funds Weigh In On Blueprint Medicines

Several large investors have recently added to or reduced their stakes in BPMC. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Blueprint Medicines by 0.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 37,414 shares of the biotechnology company’s stock worth $3,451,000 after buying an additional 145 shares during the period. US Bancorp DE increased its position in shares of Blueprint Medicines by 5.2% during the 1st quarter. US Bancorp DE now owns 3,724 shares of the biotechnology company’s stock worth $353,000 after purchasing an additional 183 shares in the last quarter. Van ECK Associates Corp lifted its holdings in Blueprint Medicines by 28.4% during the 4th quarter. Van ECK Associates Corp now owns 872 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 193 shares during the last quarter. Principal Financial Group Inc. boosted its position in Blueprint Medicines by 1.7% in the fourth quarter. Principal Financial Group Inc. now owns 14,510 shares of the biotechnology company’s stock valued at $1,338,000 after buying an additional 247 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co increased its holdings in shares of Blueprint Medicines by 3.9% during the first quarter. CANADA LIFE ASSURANCE Co now owns 6,834 shares of the biotechnology company’s stock worth $648,000 after buying an additional 256 shares in the last quarter.

About Blueprint Medicines

(Get Free Report)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.

Featured Articles

Insider Buying and Selling by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.